FLCN and metabolic dysfunction-associated steatotic liver disease: This study1 permitted selective control of liver cell metabolism by the FLCN:mTORC1:TFE3 arm and exhibited very few undesired effects in the treatment of NAFLD, thus opening up a new therapy option for NAFLD.